Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs
Osteoarthritis (OA) is a degenerative joint cartilage disease characterized pathologically by osteophytes formation and subchondral bone damage. It leads to pain, stiffness, deformation and even disability in the patients, and increases the risk of comorbidities. As its pathophysiological mechanisms...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2025-01-01
|
| Series: | Xiehe Yixue Zazhi |
| Subjects: | |
| Online Access: | https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0802 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823865251348611072 |
|---|---|
| author | CUI Hanshu LIU Bin |
| author_facet | CUI Hanshu LIU Bin |
| author_sort | CUI Hanshu |
| collection | DOAJ |
| description | Osteoarthritis (OA) is a degenerative joint cartilage disease characterized pathologically by osteophytes formation and subchondral bone damage. It leads to pain, stiffness, deformation and even disability in the patients, and increases the risk of comorbidities. As its pathophysiological mechanisms are not well understood, it is hard to identify the specific targets of OA and standardize its pharmacological treatments. Some scholars believe that synovial inflammation is the main factor of pain and progression of OA, so disease-modifying anti-rheumatic drugs (DMARDs) for inflammatory arthritis could be used to treat OA. However, others hold opposing views, arguing that inflammation is not the core driving factor of OA, and the available research results are not sufficient to support the application of DMARDs in OA. In addition, the side effects and monitoring requirements limit the application value of DMARDs in treatment of OA, especially for elderly OA patients with comorbidities. This article analyzes and discusses this debate based on the mechanisms of OA inflammation and pain, and in conjunction with relevant research findings from domestic and international studies. |
| format | Article |
| id | doaj-art-788f1acc22904253a834b170246c4f42 |
| institution | Kabale University |
| issn | 1674-9081 |
| language | zho |
| publishDate | 2025-01-01 |
| publisher | Editorial Office of Medical Journal of Peking Union Medical College Hospital |
| record_format | Article |
| series | Xiehe Yixue Zazhi |
| spelling | doaj-art-788f1acc22904253a834b170246c4f422025-02-08T07:47:34ZzhoEditorial Office of Medical Journal of Peking Union Medical College HospitalXiehe Yixue Zazhi1674-90812025-01-01161131810.12290/xhyxzz.2024-0802Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic DrugsCUI Hanshu0LIU Bin1Department of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, ChinaDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, ChinaOsteoarthritis (OA) is a degenerative joint cartilage disease characterized pathologically by osteophytes formation and subchondral bone damage. It leads to pain, stiffness, deformation and even disability in the patients, and increases the risk of comorbidities. As its pathophysiological mechanisms are not well understood, it is hard to identify the specific targets of OA and standardize its pharmacological treatments. Some scholars believe that synovial inflammation is the main factor of pain and progression of OA, so disease-modifying anti-rheumatic drugs (DMARDs) for inflammatory arthritis could be used to treat OA. However, others hold opposing views, arguing that inflammation is not the core driving factor of OA, and the available research results are not sufficient to support the application of DMARDs in OA. In addition, the side effects and monitoring requirements limit the application value of DMARDs in treatment of OA, especially for elderly OA patients with comorbidities. This article analyzes and discusses this debate based on the mechanisms of OA inflammation and pain, and in conjunction with relevant research findings from domestic and international studies.https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0802osteoarthritisdisease-modifying anti-rheumatic drugstreatmentmethotrexate |
| spellingShingle | CUI Hanshu LIU Bin Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs Xiehe Yixue Zazhi osteoarthritis disease-modifying anti-rheumatic drugs treatment methotrexate |
| title | Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs |
| title_full | Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs |
| title_fullStr | Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs |
| title_full_unstemmed | Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs |
| title_short | Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs |
| title_sort | controversy about management of osteoarthritis with disease modifying anti rheumatic drugs |
| topic | osteoarthritis disease-modifying anti-rheumatic drugs treatment methotrexate |
| url | https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0802 |
| work_keys_str_mv | AT cuihanshu controversyaboutmanagementofosteoarthritiswithdiseasemodifyingantirheumaticdrugs AT liubin controversyaboutmanagementofosteoarthritiswithdiseasemodifyingantirheumaticdrugs |